Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

NCT06261060 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT06261060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06261060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 20, 2024
Completion date
June 11, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

familial platelet disorder, hematopoietic